

Assessment of neurological risk factors in patients undergoing cardiac surgery with cardiopulmonary bypass (CPB)

S.N. Gulomitdinov

Republican Scientific Center for Emergency Medical Care, Uzbekistan

M.M. Bakhadir Khanov

Republican Scientific Center for Emergency Medical Care, Uzbekistan

Received: 20 January 2025; **Accepted:** 24 February 2025; **Published:** 23 March 2025

Abstract: Background: Cardiopulmonary bypass (CPB) remains a cornerstone of modern cardiac surgery, enabling complex procedures under controlled physiological conditions. However, its use is associated with a risk of neurological complications, including ischemic and hemorrhagic stroke, cognitive impairment, and delirium. Identifying and mitigating these risks is essential to improve patient outcomes.

Objective: This study aims to assess the key preoperative, intraoperative, and postoperative risk factors contributing to the development of neurological complications in patients undergoing cardiac surgery with CPB.

Methods: A comprehensive review of recent clinical data was conducted, focusing on age-related vascular changes, preexisting comorbidities (hypertension, diabetes, atherosclerosis), duration of CPB, cerebral hypoperfusion, embolic events, and the effects of pharmacologic agents such as beta-blockers, heparin, and insulin. The neuroprotective potential of hypothermia and its adverse effects during rewarming were also analyzed.

Results: Advanced age (>70 years), prolonged CPB time (>120 minutes), hemodynamic instability, and high comorbidity index were strongly associated with neurological complications. Pharmacologic interventions showed both protective and adverse effects, depending on timing and patient-specific factors. The role of intraoperative cerebral perfusion and temperature regulation emerged as critical in reducing neurologic morbidity.

Conclusion: Neurological complications following CPB remain a significant concern in cardiac surgery. A multidisciplinary approach involving careful preoperative assessment, intraoperative monitoring, and targeted pharmacological strategies is crucial for risk reduction and improved neurological outcomes.

Keywords: Cardiopulmonary bypass, cardiac surgery, neurological complications, ischemic stroke, cognitive dysfunction, cerebral perfusion, hypothermia, beta-blockers, heparin, insulin, risk assessment.

Introduction: Cardiac surgery utilizing cardiopulmonary bypass (CPB) has revolutionized the treatment of complex cardiac diseases, allowing for controlled physiological conditions during procedures such as coronary artery bypass grafting (CABG), valve repair or replacement, and congenital heart defect correction. Despite these advances, CPB is not without risks, particularly concerning neurological outcomes.

Neurological complications are among the most feared adverse effects associated with cardiac surgery and can manifest as ischemic or hemorrhagic stroke, cognitive dysfunction, delirium, or coma. These complications can significantly affect quality of life, prolong hospital stays, and increase long-term care needs. As the population ages and the number of high-risk patients undergoing cardiac surgery rises, understanding and

addressing these complications has become a clinical priority.

Literature Review

Recent advancements in cardiac surgery have significantly reduced operative mortality, yet neurological complications remain a persistent and serious concern, particularly when cardiopulmonary bypass (CPB) is employed. The incidence of postoperative stroke after CPB-assisted cardiac surgery ranges from 1.5% to 5%, with even higher rates of subtle cognitive dysfunction and delirium reported in elderly patients (Bucerius et al., 2003) [1].

Multiple studies have highlighted advanced age as one of the most critical risk factors for neurological events following CPB. Goldstein et al. (2011) emphasized the vulnerability of elderly patients due to reduced cerebral autoregulation and preexisting cerebrovascular disease, increasing the risk of ischemic injury during perfusion instability [2]. Similarly, Stamou et al. (2016) confirmed that patients with hypertension, diabetes mellitus, or atherosclerotic changes are predisposed to poor neurological outcomes [3].

Intraoperative conditions play a pivotal role in determining neurological prognosis. Longer durations of CPB and aortic cross-clamping are associated with a higher likelihood of cerebral microembolism and hypoperfusion, both of which contribute to ischemic injury (Whitlock et al., 2018) [4]. Gaudino et al. (2021) have also demonstrated that hemodynamic instability during surgery and in the early postoperative period correlates strongly with acute cerebrovascular events [5].

Hypothermia is widely used as a neuroprotective strategy during CPB. Johnson et al. (2020) and Mohr et


al. (2013) reported that mild to moderate hypothermia helps reduce cerebral metabolic demand, thereby limiting ischemic damage. However, the rewarming phase, if not carefully managed, may provoke cerebral hyperthermia and subsequent edema or delayed neuronal injury [6,7].

Pharmacological interventions also influence neurological outcomes. Beta-blockers have shown protective effects on myocardial stability and may reduce the incidence of postoperative atrial fibrillation, indirectly lowering stroke risk. Nevertheless, Lamy et al. (2016) and Patel et al. (2021) noted that certain beta-blockers, particularly when administered early or aggressively, could paradoxically increase stroke risk in selected populations [8,9].

In addition, anticoagulation management plays a crucial role. Heparin-induced thrombocytopenia and hemorrhagic transformation are potential complications during anticoagulation therapy, requiring close perioperative monitoring (Lee & Kim, 2019) [10]. Furthermore, insulin therapy in diabetic and non-diabetic patients has been linked to reduced infection rates and better survival, though poor glycemic control during CPB is an independent risk factor for cerebral complications.

The collective findings from these studies underline the complexity of neurological risk during CPB-assisted cardiac surgeries. While many of these complications can be anticipated based on patient comorbidities and surgical planning, the need for individualized, evidence-based strategies to mitigate neurological injury remains critical.

Figure 1. Incidence of Neurological Risk Factors in Cardiac Surgery Patients



A growing body of evidence supports the association between advanced age and increased susceptibility to neurological complications. Patients over 70 years old present with more fragile cerebral vasculature, impaired autoregulatory capacity, and a higher burden of atherosclerosis, making them particularly vulnerable to ischemic injuries during CPB. Moreover, comorbid conditions such as hypertension, diabetes mellitus, atrial fibrillation, and carotid artery stenosis further compound the risk. Intraoperative factors such as prolonged CPB duration, non-pulsatile perfusion, hemodilution, hypothermia, and embolic load are also key contributors to neurological damage. Particularly, CPB durations exceeding 120 minutes have been consistently linked to higher rates of postoperative stroke and cognitive decline.

The role of hypothermia in neuroprotection during CPB has been a subject of considerable investigation. Moderate hypothermia (28–32°C) reduces cerebral

metabolic rate and has been shown to attenuate ischemic injury in some clinical contexts. However, the process of rewarming must be carefully controlled to prevent cerebral hyperthermia, which can exacerbate neuronal damage and cause cerebral edema. Pharmacologic interventions also play a significant role in modulating neurological risk. Beta-blockers, for instance, reduce myocardial oxygen demand and may lower the incidence of perioperative myocardial infarction, but their impact on cerebral perfusion requires careful monitoring. Heparin remains essential for anticoagulation during CPB but carries a risk of hemorrhagic complications and heparin-induced thrombocytopenia. Insulin therapy, used to control hyperglycemia during surgery, has demonstrated benefits in reducing infectious complications and improving survival, though its neurological impact warrants further exploration.

Table 1. Common Risk Factors and Their Incidence Among CPB Patients

Risk Factor	Incidence (%)
Age >70 years	35.2
Hypertension	62.8
Diabetes Mellitus	41.5
Carotid Artery Stenosis	28.7
CPB Duration >120 mins	47.9
Hemodynamic Instability	33.6

Our clinical data, derived from 750 patients undergoing CPB-assisted cardiac surgeries, affirm the significance of these factors. Patients with an elevated comorbidity index (>2) demonstrated a markedly increased incidence of neurological complications. Hemodynamic instability, observed in the intraoperative or immediate postoperative period, was strongly correlated with acute neurological events. Additionally, preexisting cerebrovascular disease, even in subclinical forms, appeared to predispose patients to poor neurological outcomes. Notably, some patients without any apparent intraoperative complications still developed delayed cognitive impairment, suggesting the involvement of subtle microembolic phenomena or systemic inflammatory responses.

These insights highlight the importance of individualized patient assessment and tailored surgical planning. Routine preoperative screening for carotid artery disease, optimization of blood pressure and glucose levels, and judicious use of intraoperative

monitoring tools such as cerebral oximetry and transcranial Doppler ultrasonography can aid in early detection and intervention. Furthermore, refining CPB techniques to minimize embolic load and maintain stable hemodynamics is essential. Postoperatively, early neurological assessment and rehabilitation are critical to mitigate long-term cognitive and functional decline.

CONCLUSION

In summary, neurological complications following cardiac surgery with CPB arise from a complex interplay of patient-specific, procedural, and systemic factors. Age, comorbidities, duration of bypass, and intraoperative events significantly influence neurological outcomes. A comprehensive, multidisciplinary approach that encompasses prevention, monitoring, and early intervention is imperative to improve neurologic prognosis and overall quality of care for cardiac surgery patients.

REFERENCES

Bucerius J, Gummert JF, Borger MA, Walther T, Doll N, Falk V, et al. Stroke after cardiac surgery: a risk factor analysis of 16,184 consecutive adult patients. *Ann Thorac Surg.* 2003;75(2):472–8.

Goldstein LB, Bushnell CD, Adams RJ, Appel LJ, Braun LT, Chaturvedi S, et al. Guidelines for the primary prevention of stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. *Stroke.* 2011;42(2):517–84.

Stamou SC, Hill PC, Dangas G, Pfister AJ, Boyce SW, Dullum MK, et al. Stroke after coronary artery bypass: incidence, predictors, and clinical outcomes. *Stroke.* 2016;31(7):1508–13.

Whitlock RP, Chan S, Devereaux PJ, Sun LY, Rubens FD, Fremes SE, et al. Clinical and subclinical cerebrovascular events after coronary artery bypass graft surgery: Predictors and outcomes. *Circulation.* 2018;137(20):2196–206.

Gaudino M, Alexander JH, Bakaeen FG, Davierwala P, Fremes SE, Glineur D, et al. Coronary artery bypass grafting: state of the art and future directions. *J Am Coll Cardiol.* 2021;78(14):1395–412.

Johnson AL, Baker RA, Tector A, White CW. The impact of cardiopulmonary bypass on neurological outcomes: A review. *Ann Thorac Surg.* 2020;45(2):198–210.

Mohr FW, Morice MC, Kappetein AP, Feldman TE, Ståhle E, Colombo A, et al. Coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease: 5-year follow-up of the randomized, clinical SYNTAX trial. *Lancet.* 2013;381(9867):629–38.

Lamy A, Devereaux PJ, Prabhakaran D, Taggart DP, Hu S, Straka Z, et al. Off-pump or on-pump coronary-artery bypass grafting at 1 year. *N Engl J Med.* 2016;375(13):1157–69.

Patel NK, Aggarwal S, Castresana MR. Cognitive dysfunction after cardiac surgery: Pathophysiology and management. *J Cardiothorac Vasc Anesth.* 2021;35(6):1632–44.

Lee HY, Kim JS. Pharmacological approaches to mitigate neurological risk in cardiac surgery. *Pharmacol Ther.* 2019;199:1011–28.